Attenuation of Graft Arterial Disease by Manipulation of the LIGHT Pathway
- 1 August 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 24 (8) , 1409-1415
- https://doi.org/10.1161/01.atv.0000134645.53285.02
Abstract
Objective—The tumor necrosis factor (TNF) superfamily member LIGHT, which binds herpes virus entry mediator (HVEM) and lymphotoxin β receptor (LTβR), plays important roles in regulating the immune response. To clarify the mechanism underlying graft arterial disease (GAD), we investigated the role of the LIGHT pathway in the progression of GAD.Methods and Results—Hearts from Bm12 mice were transplanted into C57BL/6 (B/6) mice (class II mismatch). Recipients were injected intraperitoneally with HVEMIg (100 μg per treatment) every 7 days for 8 weeks. Treatment with HVEMIg significantly attenuated GAD (luminal occlusion=16.5±7.7% versus control allograft=62.6±12.1%,PConclusions—These results indicate that the LIGHT pathway plays important roles in the regulation not only of T-cell activation but also of SMC proliferation. Blockade of the LIGHT pathway is a promising avenue for the prevention of GAD.Keywords
This publication has 24 references indexed in Scilit:
- Targeted Disruption of LIGHT Causes Defects in Costimulatory T Cell Activation and Reveals Cooperation with Lymphotoxin β in Mesenteric Lymph Node GenesisThe Journal of Experimental Medicine, 2002
- Modulation of LIGHT-HVEM Costimulation Prolongs Cardiac Allograft SurvivalThe Journal of Experimental Medicine, 2002
- Interleukin-10 (IL-10) Augments Allograft Arterial DiseaseThe American Journal of Pathology, 1999
- Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejectionJournal of Clinical Investigation, 1999
- LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer.Journal of Clinical Investigation, 1998
- Persistent and Secondary Adenovirus-Mediated Hepatic Gene Expression Using Adenovirus Vector Containing CTLA4IgGHuman Gene Therapy, 1998
- LIGHT, a New Member of the TNF Superfamily, and Lymphotoxin α Are Ligands for Herpesvirus Entry MediatorImmunity, 1998
- Herpesvirus Entry Mediator, a Member of the Tumor Necrosis Factor Receptor (TNFR) Family, Interacts with Members of the TNFR-associated Factor Family and Activates the Transcription Factors NF-κB and AP-1Journal of Biological Chemistry, 1997
- Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathwaysNature, 1996
- Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis.Journal of Clinical Investigation, 1996